Ribon Therapeutics Names Parasuraman as Chief Medical Officer, Stewart as Chief Business Officer
8 August 2019 - - US-based clinical stage biotechnology company Ribon Therapeutics has named Sudha Parasuraman, M.D., and Edward "Tad" Stewart to the newly created positions of chief medical officer and chief business officer, respectively, the company said.

Parasuraman is a board-certified hematologist-oncologist with more than 20 years in the healthcare industry and broad experience across the spectrum of oncology drug development.

Stewart brings more than 20 years of executive experience in the biotechnology area with a focus on business development, strategy and commercialisation.

Parasuraman brings more than 20 years of industry and academic practice experience in hematology, oncology, and pediatrics to her work at Ribon.

Most recently she served as CMO for X4 Pharmaceuticals, where she led their immuno-oncology and rare disease programs. Prior to X4, she was VP, global medical affairs at uniQure Inc, where she built and led a team developing gene therapies for rare diseases.

Prior to uniQure, she held senior positions at Novartis, where she led the early development program for the CDK4/6 inhibitor, ribociclib, and helped pave the way for accelerated registration studies.

She was responsible for leading innovative clinical trials in the Signature Program and the commercial strategies for early-stage programs.

Parasuraman also served as medical director at Millennium Pharmaceuticals (now Takeda Oncology) where she was the medical lead for various programs including the clinical development and lifecycle management of the first-in-class cancer therapy, Velcade.

Before joining industry, Parasuraman was a faculty member at Harvard Medical School and staff physician at Children's Hospital of Boston, Dana Farber Cancer Institute, and Brigham and Women's Hospital.

Parasuraman completed her fellowship in pediatric hematology-oncology at St. Jude Children's Research Hospital in Memphis, TN, and pediatric residencies at Children's Hospital of Michigan and Los Angeles County/University of Southern California Medical Center.

She received her medical degree from the University of Madras, India.

Stewart has more than 20 years of strategic biopharmaceutical business development experience, including over fifteen years at Merrimack Pharmaceuticals.

During his time at Merrimack, Stewart served in various roles as part of the executive leadership team, including leading the company's business development efforts and heading the company's Commercial Business Unit.

Stewart's experience at Merrimack spanned its growth from a pre-clinical organization to a clinical development company and, ultimately, to a commercial enterprise, including the successful launch of a marketed oncology product (ONIVYDE) and the execution of several strategic transactions that supported the long-term growth of the company.

Most recently he served as president and CEO of Commense, Inc., a company focused on developing pediatric immunomodulators based on manipulating the human microbiome.

Prior to Commense, Stewart served as CBO for Crescendo Biologics, a novel antibody platform company. Prior to Merrimack, Stewart worked as a consultant with clients across the biotech, pharmaceutical and medical device industries. Tad holds an M.B.A. from the Johnson School at Cornell University and a B.S. in Biology from Bates College.

Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

The company is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options.

Leveraging a chemical biology approach and our proprietary discovery platform, Ribon is building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilising enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas.

Ribon's lead programme is RBN-2397, a first-in-class PARP7 inhibitor in development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts.